Home » Authors » Trista Morrison

Articles by Trista Morrison

Spin-Out Sequel Pharma Closes $20M Series A

Sep. 28, 2007

By Trista Morrison

Spin-Out Sequel Pharma Closes $20M Series A

Sep. 28, 2007

By Trista Morrison

Partnering Tables Turn As Big Pharma Pitches Biotech

Sep. 27, 2007

By Trista Morrison

Partnering Tables Turn As Big Pharma Pitches Biotech

Sep. 27, 2007

By Trista Morrison

Embryonic Stem Cell Research Advances, But Obstacles Remain

Sep. 26, 2007

By Trista Morrison

Embryonic Stem Cell Research Advances, But Obstacles Remain

Sep. 26, 2007

By Trista Morrison

Virxsys Acquires Intronn, Gets RNA Payloads For Gene Therapy

Sep. 24, 2007

By Trista Morrison

Virxsys Acquires Intronn, Gets RNA Payloads For Gene Therapy

Sep. 24, 2007

By Trista Morrison

Progenics Raises $57M Publicly; Cellerix Gets $40M In Series B

Sep. 21, 2007

By Trista Morrison

NewCo News: ImmunoBiosciences Using ICV Platform To Improve Vaccines

Sep. 21, 2007

By Trista Morrison

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...